Firm expects to have 80% of US sows on the PRP programme by 2030
GENUS (GNS) Price: £21.80 Market Cap: £1.45 billion Leading global animal genetics company Genus (GNS) is on the cusp of fully commercialising its proprietary PRP (PRRS or Porcine Reproductive and Respiratory Syndrome virus-resistant pig) technology. This could be transformational for farmers in the porcine industry who have seen their herds decimated by the virus over many years. A recent study from Iowa State University reported the devastating virus costs...